Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan/HDS in hepatic-dominant ocular melanoma
2015-000417-44Phase 3Unknown
- Sponsor
- Delcath Systems
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of melphalan in eye melanoma, sponsored by Delcath Systems. Primary endpoint: Objective Response Rate by IRC. Status: unknown.
02
Drugs
melphalan
03
Conditions
eye melanoma
Beyond the preview
Go deeper on 2015-000417-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000417-44.